180 related articles for article (PubMed ID: 26254098)
1. Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission.
Cha Z; Li C; Zang Y; Gu H; Guo H; Li J; Fang Y; Petersen TF; Li J; Karas RO; Hamilton ML; Qian B
Tumour Biol; 2016 Jan; 37(1):829-35. PubMed ID: 26254098
[TBL] [Abstract][Full Text] [Related]
2. CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
Qiu H; Li J; Feng Z; Yuan J; Lu J; Hu X; Gao L; Lv S; Yang J; Chen L
Clin Exp Pharmacol Physiol; 2016 Sep; 43(9):795-801. PubMed ID: 27247195
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T cell-mediated cytotoxicity is associated with MHC class II expression on malignant CD19+ B cells in diffuse large B cell lymphoma.
Zhou Y; Zha J; Lin Z; Fang Z; Zeng H; Zhao J; Luo Y; Li Z; Xu B
Exp Cell Res; 2018 Jan; 362(2):287-292. PubMed ID: 29174982
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
6. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
7. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
8. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
Tokunaga T; Tomita A; Sugimoto K; Shimada K; Iriyama C; Hirose T; Shirahata-Adachi M; Suzuki Y; Mizuno H; Kiyoi H; Asano N; Nakamura S; Kinoshita T; Naoe T
Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
[TBL] [Abstract][Full Text] [Related]
9. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
10. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
11. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
12. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
13. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
[TBL] [Abstract][Full Text] [Related]
14. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
16. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.
Fujiwara S; Muroi K; Hirata Y; Sato K; Matsuyama T; Ohmine K; Suzuki T; Ozaki K; Mori M; Nagai T; Tanaka A; Ozawa K
Hematology; 2013 Jan; 18(1):14-9. PubMed ID: 22981118
[TBL] [Abstract][Full Text] [Related]
18. Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma.
Coleman M; Lammers PE; Ciceri F; Jacobs IA
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):175-81. PubMed ID: 26906106
[TBL] [Abstract][Full Text] [Related]
19. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
20. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
Deng L; Xu-Monette ZY; Loghavi S; Manyam GC; Xia Y; Visco C; Huh J; Zhang L; Zhai Q; Wang Y; Qiu L; Dybkær K; Chiu A; Perry AM; Zhang S; Tzankov A; Rao H; Abramson J; Sohani AR; Xu M; Hsi ED; Zhu J; Ponzoni M; Wang S; Li L; Zhang M; Ferreri AJ; Parsons BM; Li Y; Piris MA; Medeiros LJ; Young KH
Leukemia; 2016 Feb; 30(2):361-72. PubMed ID: 26308769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]